JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 243 filers reported holding JUNO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.8%.
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 17,348,799 | $653,858,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $61,042,000 | 83.87% |
| Omega Fund Management, LLC | 1,229,512 | $46,832,000 | 32.48% |
| Clarius Group, LLC | 114,396 | $4,357,000 | 2.42% |
| AlpInvest Partners B.V. | 30,000 | $1,143,000 | 2.18% |
| BB BIOTECH AG | 1,305,000 | $49,707,000 | 1.98% |
| First Washington CORP | 39,200 | $1,493,000 | 0.88% |
| Baillie Gifford | 10,918,377 | $415,880,000 | 0.73% |
| HAMILTON LANE ADVISORS LLC | 40,000 | $1,524,000 | 0.73% |
| Rock Springs Capital Management LP | 197,001 | $7,504,000 | 0.63% |